Metastatic Pancreatic Cancer – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Metastatic Pancreatic Cancer - Pipeline Review, H1 2012', provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer. 'Metastatic Pancreatic Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Pancreatic Cancer.
- A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Metastatic Pancreatic Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
[Studien Infos ausblenden]

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Pancreatic Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Metastatic Pancreatic Cancer 10
Metastatic Pancreatic Cancer Therapeutics under Development by Companies 12
Metastatic Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Metastatic Pancreatic Cancer Therapeutics – Products under Development by Companies 24
Metastatic Pancreatic Cancer Therapeutics – Products under Investigation by Universities/Institutes 26
Companies Involved in Metastatic Pancreatic Cancer Therapeutics Development 35
F. Hoffmann-La Roche Ltd. 35
Amgen Inc. 36
Eli Lilly and Company 37
Infinity Pharmaceuticals, Inc. 38
FibroGen, Inc. 39
Astellas Pharma Inc. 40
Chugai Pharmaceutical Co. Ltd 41
Pfizer Inc. 42
Celgene Corporation 43
Bayer AG 44
IMMUNOMEDICS, INC 45
Oncolytics Biotech Inc. 46
NanoCarrier Co., Ltd. 47
Rexahn Pharmaceuticals, Inc. 48
Oncoscience AG 49
MacroGenics, Inc. 50
OncoMed Pharmaceuticals, Inc. 51
Immutep S.A. 52
AB Science 53
Clovis Oncology, Inc. 54
Theradex Systems, Inc. 55
Metastatic Pancreatic Cancer – Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 63
AMG-479 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Abraxane - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CP-4126 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Gemcitabine + Tarceva - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
IMC-C225 + Gemcitabine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Gemcitabine hydrochloride - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Gemcitabine + Dalteparin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AMG 479 + Gemzar - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Capecitabine + Gemcitabine - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Gemcitabine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Abraxane + Gemzar - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Gemcitabine + Capecitabine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Gemcitabine + Sorafenib - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Gemcitabine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Gemcitabine hydrochloride - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
AB1010 + Gemcitabine - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Gemcitabin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Nimotuzumab + Gemcitabine - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Erlotinib Hydrochloride + Gemcitabine Hydrochloride - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Bevacizumab + Gemcitabine - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Gemcitabine - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Gemcitabine + Capecitabine - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Gemcitabine + Capecitabine + Telovac + GM-CSF - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 98
Metastatic Pancreatic Cancer Therapeutics – Drug Profile Updates 99
Metastatic Pancreatic Cancer Therapeutics – Discontinued Products 104
Metastatic Pancreatic Cancer Therapeutics - Dormant Products 105
Metastatic Pancreatic Cancer – Product Development Milestones 111
Featured News & Press Releases 111
Jan 09, 2012: Clovis Oncology Announces Pivotal Trial Results Of CO-101 111
Jul 20, 2011: NanoCarrier Commences Phase II Study Of Nanoplatin 111
Jun 08, 2011: PharmaMar Commences Phase II Trials With PM01183 In Metastatic Pancreatic Cancer 112
May 19, 2011: Infinity Announces Clinical Data Of IPI-926 To Be Presented At ASCO 112
Mar 23, 2011: Tragara To Present Apricoxib Posters At 2011 AACR 102nd Annual Meeting 112
Jan 21, 2011: FibroGen Reports Interim Results Of Phase I/II Trial Of FG-3019 In Metastatic Pancreatic Cancer 113
Sep 02, 2010: Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Agensys 114
Jul 20, 2010: Seattle Genetics And Agensys Initiate Phase I Clinical Trial Of ASG-5ME For Metastatic Pancreatic Cancer 114
Jun 07, 2010: Clivatuzumab Tetraxetan Shows Promising Results In Patients With Metastatic Pancreatic Cancer 115
Jun 07, 2010: Immunomedics Reports Updated Results Of Targeted Therapy For Advanced Pancreatic Cancer 116
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 119
Contact Us 119
Disclaimer 119
[Inhaltsverzeichnis ausblenden]

List of Tables
Number of Products Under Development for Metastatic Pancreatic Cancer, H1 2012 10
Products under Development for Metastatic Pancreatic Cancer – Comparative Analysis, H1 2012 11
Number of Products under Development by Companies, H1 2012 13
Number of Products under Development by Companies, H1 2012 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2012 16
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 19
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 20
Comparative Analysis by Late Stage Development, H1 2012 21
Comparative Analysis by Mid Clinical Stage Development, H1 2012 22
Comparative Analysis by Early Clinical Stage Development, H1 2012 23
Products under Development by Companies, H1 2012 24
Products under Development by Companies, H1 2012 (Contd..1) 25
Products under Investigation by Universities/Institutes, H1 2012 26
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 27
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 28
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 30
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 31
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 32
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 33
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 34
F. Hoffmann-La Roche Ltd., H1 2012 35
Amgen Inc., H1 2012 36
Eli Lilly and Company, H1 2012 37
Infinity Pharmaceuticals, Inc., H1 2012 38
FibroGen, Inc., H1 2012 39
Astellas Pharma Inc., H1 2012 40
Chugai Pharmaceutical Co. Ltd, H1 2012 41
Pfizer Inc., H1 2012 42
Celgene Corporation, H1 2012 43
Bayer AG, H1 2012 44
IMMUNOMEDICS, INC, H1 2012 45
Oncolytics Biotech Inc., H1 2012 46
NanoCarrier Co., Ltd., H1 2012 47
Rexahn Pharmaceuticals, Inc., H1 2012 48
Oncoscience AG, H1 2012 49
MacroGenics, Inc., H1 2012 50
OncoMed Pharmaceuticals, Inc., H1 2012 51
Immutep S.A., H1 2012 52
AB Science, H1 2012 53
Clovis Oncology, Inc., H1 2012 54
Theradex Systems, Inc., H1 2012 55
Assessment by Monotherapy Products, H1 2012 56
Assessment by Combination Products, H1 2012 57
Assessment by Stage and Route of Administration, H1 2012 59
Assessment by Molecule Type, H1 2012 62
Metastatic Pancreatic Cancer Therapeutics – Drug Profile Updates 99
Metastatic Pancreatic Cancer Therapeutics – Discontinued Products 104
Metastatic Pancreatic Cancer Therapeutics – Dormant Products 105
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..1) 106
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..2) 107
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..3) 108
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..4) 109
Metastatic Pancreatic Cancer Therapeutics – Dormant Products (Contd..5) 110
List of Figures
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2012 10
Products under Development for Metastatic Pancreatic Cancer – Comparative Analysis, H1 2012 11
Products under Development by Companies, H1 2012 12
Products under Investigation by Universities/Institutes, H1 2012 15
Late Stage Products, H1 2012 21
Mid Clinical Stage Products, H1 2012 22
Early Clinical Stage Products, H1 2012 23
Assessment by Monotherapy Products, H1 2012 56
Assessment by Combination Products, H1 2012 57
Assessment by Route of Administration, H1 2012 58
Assessment by Stage and Route of Administration, H1 2012 59
Assessment by Molecule Type, H1 2012 60
Assessment by Stage and Molecule Type, H1 2012 61
[Tabellenverzeichnis ausblenden]